- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Vasculitis drug CCX168 to address major unmet needs, says GlobalData
25 May 2016 • Author: Victoria White, Digital Content Producer
CCX168 is a potent orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR, and is the lead drug candidate in ChemoCentryx’s orphan and rare disease programme.
Alexandra Annis, MS, GlobalData’s Analyst covering Immunology, states: “The majority of those currently diagnosed with AVV achieve remission, but a substantial risk of relapse means that they face a prolonged duration of maintenance therapy, resulting in long-term exposure to therapies with significant side effects. Long exposure to Rituxan or methotrexate, for example, is associated with significant side effects and must be administered in conjunction with glucocorticoids (GC).”
Reducing the overall treatment burden
As explored in GlobalData’s vasculitis report, there are a vast number of unmet needs in the treatment space, and new drugs are needed to reduce the overall treatment burden of current therapy options.
Annis explains: “CCX168, which was recently awarded an Orphan Products Development grant by the FDA, could address this, and has demonstrated an impressive safety and efficacy profile in the Phase II European CLEAR study, designed to assess whether it could replace the use of high-dose, chronic GCs without compromising efficacy.
“In terms of the potential competition CCX168 may face in the AAV market, GlobalData expects that the drug will hold an advantage over several competitors due to attractive pricing.
“For example, Bristol-Myers Squibb’s Orencia (abatacept) and GlaxoSmithKline’s Benlysta (belimumab) may be able to completely replace GCs, and are expected to hit the market before CCX168, which is not expected to launch until after 2024. However, Orencia and Benlysta are expected to be priced at around $40,000 and $50,000 per patient per year, respectively, meaning CCX168 may hold the upper hand given its anticipated lower price point as a small molecule.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics